PharmaCyte Biotech Inc
PMCB
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.91M
Close$
$2.07
244.4% upside
Current Fair Value
244.4% upsideUndervalued by 244.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.91 Million |
|---|---|
| Enterprise Value | $-18,603,895,085,631.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.77 |
| Beta | 0.52 |
| Outstanding Shares | 10,735,649 |
Return
| Return on Equity | -0.00% |
|---|---|
| Return on Assets | -0.00% |
| Return on Invested Capital | -0.00% |
Valuation & Multiples
| P/E Ratio | -0.19 |
|---|---|
| PEG | 0.15 |
| Price to Sales | - |
| Price to Book Ratio | 0.0 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 1442597.31 |
| Enterprise Value to Net Income | 4346436 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 29, 2026
EPS Estimate
$-0.06
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 24, 2026
EPS Estimate
$-0.06
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 160,200▼ 13.92% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 10.44%▼ 0.18% |
|---|---|
| Total Invested | $643,180▼ 9.66% |
| Investors Holding | 33▲ 6.00% |
ESG Score
No data
About PharmaCyte Biotech Inc
4 employeesPharmaCyte Biotech, Inc. is a biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as "Cell-in-a-Box®." This technology is being use...